WBR0509: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (refreshing WBR questions)
 
(7 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor=[[User:Gonzalo Romero|Gonzalo A. Romero, M.D.]] [mailto:gromero@wikidoc.org]
|QuestionAuthor= {{SSK}} (Reviewed by Serge Korjian)
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Pharmacology
|MainCategory=Pharmacology
Line 8: Line 8:
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|SubCategory=Reproductive
|SubCategory=Reproductive
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|MainCategory=Pharmacology
Line 20: Line 21:
|MainCategory=Pharmacology
|MainCategory=Pharmacology
|SubCategory=Reproductive
|SubCategory=Reproductive
|Prompt=A 61-year-old male comes to the clinic due to hair loss.  He has a progressive history of baldness. He has tried many topical ointments and different products seen on TV, which have not been very helpful.  He would like to look younger and to prevent losing further hair.  The family doctor considers using Finasteride to treat his condition. Which of the following is true about the mechanism of action of this drug?
|Prompt=A 31-year-old man presents to the dermatology clinic for hair loss.  The patient reports progressive hairline regression and hair loss mainly localized above the temples and at the vertex.  He also explains that he has a strong family history of androgenetic alopecia, and cannot stand the idea of going completely bald. The patient has tried many topical products intended for hair loss, which have not been very helpful.  You consider using an agent that is also approved for the treatment of benign prostatic hyperplasia. Which of the following is the most likely mechanism of action of this drug?
|Explanation=Finasteride is used for [[BPH]] (benigh prostatic hyperplasia) and to treat male-pattern baldness,because it promotes hair growth. It is an 5 alfa-reductase inhibitor (normally converts [[testosterone]] to [[DHT]]), decreasing the conversion of testosterone to DHT (dihydrotestosterone).
|Explanation=Finasteride is a selective inhibitor of 5-alpha-reductase that suppresses serum dihydrotestosterone (DHT) levels by inhibiting the conversion of testosterone to DHT. Finasteride may be used alone or in combination with alpha-blockers to treat benign prostatic hyperplasia (BPH). Another indication finasteride is slowing the progression of androgenetic alopecia. As androgenetic alopecia is partly caused by the effect of DHT at the pilosebaceous unit, decreasing DHT production is associated with slower progression of hair loss. Finasteride actively delays hair loss while the medication is being administered; however, similarly to other medical options for the treatment of alopecia, its effect does not last once the drug is discontinued. Common side effects include erectile dysfunction, decreased libido, and breast enlargement.
|AnswerA=It is a non-steroidal competitive inhibitor of androgens at the testosterone receptor
|AnswerA=Phosphodiesterase 5 (PDE5) inhibitor
|AnswerAExp=<font color="red">'''Incorrect.'''</font>This refers to the mechanism of action of [[flutamide]] which is used in [[prostatic carcinoma]].
|AnswerAExp=Sildenafil and tadalafil are examples of phosphodiesterase 5 (PDE5) inhibitors. These drugs are used to treat erectile dysfunction and are not used for the treatment of androgenetic alopecia.
|AnswerB=Inhibits the synthesis of steroid
|AnswerB=Competitive inhibitor of testosterone binding at androgen receptors
|AnswerBExp=<font color="red">'''Incorrect.'''</font> [[Ketoconazole]] inhibits steroid synthesis by inhibiting desmolase (normally converts cholesterol to [[pregnenolone]]). ACTH stimulates the activity of desmolase.  
|AnswerBExp=Flutamide is a nonsteroidal antiandrogen that acts as a competitive inhibitor of testosterone binding at androgen receptors. It is used in the treatment of prostate cancer and is not used for the treatment of androgenetic alopecia.
|AnswerC=Inhibits the conversion of testosterone to DHT
|AnswerC=Aromatase inhibitor
|AnswerCExp=<font color="Green">'''Correct.'''</font> It is incorrect because
|AnswerCExp=Exemestane acts as an aromatase inhibitor to decrease peripheral estrogen production. It is used in the treatment of estrogen receptor-positive breast cancer and cannot be used to treat androgenetic alopecia.
|AnswerD=Inhibits steroid binding
|AnswerD=Agonist of luteinizing hormone-releasing hormone (LHRH)
|AnswerDExp=<font color="red">'''Incorrect.'''</font> [[ Spironolactone]] inhibits the androgen binding to its receptors.  It is a potasium sparing diuretic. [[Flutamide]] and cyproterone also inhibit the androgen-receptor interaction.
|AnswerDExp=Leuprolide acts as an agonist of luteinizing hormone-releasing hormone (LHRH) causing a disruption of gonadotropin release if given continuously. It is used in the treatment of prostate cancer, endometriosis, and leiomyoma and cannot be used to treat androgenetic alopecia.
|AnswerE=Binds to estrogen receptors
|AnswerE=Selective inhibitor of 5-alpha-reductase
|AnswerEExp=<font color="red">'''Incorrect.'''</font>  [[Estrogens]] such as ethinyl estradiol, DES, mestranol bind to estrogen receptors, acting as agonists. Estrogen receptor antagonists include [[tamoxifen]], [[raloxifene]] and [[fulvestrant]].
|AnswerEExp=Finasteride is a selective inhibitor of 5-alpha-reductase used in the treatment of androgenetic alopecia.
|RightAnswer=C
|EducationalObjectives=Finasteride is a selective inhibitor of 5-alpha-reductase used in the treatment of androgenetic alopecia.
|WBRKeyword=Testosterone agonist, testosterone antagonist
|References=Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39(4 Pt 1):578-89.
|Approved=No
|RightAnswer=E
|WBRKeyword=Androgenetic alopecia, Male pattern baldness, baldness, Finasteride, 5-alpha-reductase, DHT, Testosterone,  
|Approved=Yes
}}
}}

Latest revision as of 00:48, 28 October 2020

 
Author [[PageAuthor::Serge Korjian M.D. (Reviewed by Serge Korjian)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pharmacology
Sub Category SubCategory::Reproductive
Prompt [[Prompt::A 31-year-old man presents to the dermatology clinic for hair loss. The patient reports progressive hairline regression and hair loss mainly localized above the temples and at the vertex. He also explains that he has a strong family history of androgenetic alopecia, and cannot stand the idea of going completely bald. The patient has tried many topical products intended for hair loss, which have not been very helpful. You consider using an agent that is also approved for the treatment of benign prostatic hyperplasia. Which of the following is the most likely mechanism of action of this drug?]]
Answer A AnswerA::Phosphodiesterase 5 (PDE5) inhibitor
Answer A Explanation AnswerAExp::Sildenafil and tadalafil are examples of phosphodiesterase 5 (PDE5) inhibitors. These drugs are used to treat erectile dysfunction and are not used for the treatment of androgenetic alopecia.
Answer B AnswerB::Competitive inhibitor of testosterone binding at androgen receptors
Answer B Explanation AnswerBExp::Flutamide is a nonsteroidal antiandrogen that acts as a competitive inhibitor of testosterone binding at androgen receptors. It is used in the treatment of prostate cancer and is not used for the treatment of androgenetic alopecia.
Answer C AnswerC::Aromatase inhibitor
Answer C Explanation AnswerCExp::Exemestane acts as an aromatase inhibitor to decrease peripheral estrogen production. It is used in the treatment of estrogen receptor-positive breast cancer and cannot be used to treat androgenetic alopecia.
Answer D AnswerD::Agonist of luteinizing hormone-releasing hormone (LHRH)
Answer D Explanation [[AnswerDExp::Leuprolide acts as an agonist of luteinizing hormone-releasing hormone (LHRH) causing a disruption of gonadotropin release if given continuously. It is used in the treatment of prostate cancer, endometriosis, and leiomyoma and cannot be used to treat androgenetic alopecia.]]
Answer E AnswerE::Selective inhibitor of 5-alpha-reductase
Answer E Explanation AnswerEExp::Finasteride is a selective inhibitor of 5-alpha-reductase used in the treatment of androgenetic alopecia.
Right Answer RightAnswer::E
Explanation [[Explanation::Finasteride is a selective inhibitor of 5-alpha-reductase that suppresses serum dihydrotestosterone (DHT) levels by inhibiting the conversion of testosterone to DHT. Finasteride may be used alone or in combination with alpha-blockers to treat benign prostatic hyperplasia (BPH). Another indication finasteride is slowing the progression of androgenetic alopecia. As androgenetic alopecia is partly caused by the effect of DHT at the pilosebaceous unit, decreasing DHT production is associated with slower progression of hair loss. Finasteride actively delays hair loss while the medication is being administered; however, similarly to other medical options for the treatment of alopecia, its effect does not last once the drug is discontinued. Common side effects include erectile dysfunction, decreased libido, and breast enlargement.

Educational Objective: Finasteride is a selective inhibitor of 5-alpha-reductase used in the treatment of androgenetic alopecia.
References: Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39(4 Pt 1):578-89.]]

Approved Approved::Yes
Keyword WBRKeyword::Androgenetic alopecia, WBRKeyword::Male pattern baldness, WBRKeyword::baldness, WBRKeyword::Finasteride, WBRKeyword::5-alpha-reductase, WBRKeyword::DHT, WBRKeyword::Testosterone
Linked Question Linked::
Order in Linked Questions LinkedOrder::